An impedimetric immunosensor for the selective detection of CD34+ T-cells in human serum

An impedimetric immunosensor for the selective detection of CD34+ T-cells in human serum
复制标题

DOI:
10.1016/j.snb.2021.131306
复制
发表时间:
2022-01-06
影响因子:
8.4
通讯作者:
Di Lorenzo, Mirella
Di Lorenzo, Mirella
中科院分区:
化学1区
文献类型:
--
作者:
Diaz-Fernandez, Ana;Bernalte, Elena;Di Lorenzo, Mirella

文献摘要

被引文献

相似文献

Y嵌合抗原受体T(CAR-T)细胞治疗导致了癌症治疗的范式转变。为了能够广泛使用这种疗法,在确保高质量生产的同时,降低与细胞制造相关的成本是很重要的。在线生物传感器可以帮助实时监控工程CAR-T细胞的有效性,可以集成到工作流程中,而不需要提取样本进行离线分析,这需要专业人员和昂贵的分析设备。在此背景下,我们提出了一种创新的无标记阻抗免疫传感器,用于检测人血清中CD34(+)T细胞。该传感器基于丝网印刷的金电极,带有抗CD34抗体,通过11-巯基十一酸和6-巯基-1-己醇的混合自组装单层,识别表达在T细胞表面的CD34抗原。该免疫传感器在人血清中具有很高的选择性和较宽的工作范围,在法拉第和非法拉第两种检测条件下,分别为230-1.4×10(3)细胞和50-1×10(5)细胞(-1)。这一结果,以及在批处理和流通式操作中的性能验证,证明了所开发的免疫传感器在临床上的适用性。
Y Chimeric antigen receptor T (CAR-T) cell therapy has led to a paradigm change in cancer treatment. To allow widespread use of this therapy, it is important to reduce the costs associated with cells manufacturing whilst ensuring a high-quality production. Online biosensors can help monitor in real time the effectiveness of engineering CAR-T cells, with the possibility to be integrated on the workflow without the need to extract samples for off line analysis that require specialised personnel and expensive analytical equipment. In this context, we present an innovative label-free impedimetric immunosensor for the detection of CD34(+) T-cells in human serum. The sensor is based on screen-printed gold electrodes functionalised with anti-CD34 antibody, via a mixed self-assembled monolayer of 11-mercaptoundecanoic acid and 6-mercapto-1-hexanol, which recognizes the CD34 antigen expressed onto the T-cells surfaces. The immunosensor exhibits a high selectivity and a wide working range in human serum, both in Faradaic and non-Faradaic detection conditions, being respectively of 230 - 1.4 x 10(3) cell mL(-1) and 50 - 1 x 10(5) cell mL(-1). This result, along with performance validation both in batch and flow-through operations, demonstrates the applicability of the developed immunosensor for clinical use.